Literature DB >> 28494854

Yangfei Kongliu Formula, a compound Chinese herbal medicine, combined with cisplatin, inhibits growth of lung cancer cells through transforming growth factor-β1 signaling pathway.

Shui-Jie Shen1,2, Yong-Hong Zhang1, Xiao-Xia Gu2, Shui-Ju Jiang3, Ling-Jun Xu2.   

Abstract

OBJECTIVE: To investigate the tumor inhibition effect of Yangfei Kongliu Formula (YKF), a compound Chinese herbal medicine, combined with cisplatin (DDP) and its action mechanisms.
METHODS: C57BL/6 mice with Lewis lung carcinoma were divided into six groups: control group (C), DDP group (2 mg/kg, DDP), low-dose YKF group (2.43 g/kg, L), high-dose YKF group (24.3 g/kg, H), low-dose YKF combined with DDP group (L + DDP) and high-dose YKF combined with DDP group (H + DDP). Transforming growth factor-β1 (TGF-β1), mothers against decapentaplegic homolog 3 (Smad3) and Smad7 levels were measured with quantitative real-time polymerase chain reaction (qPCR), Western blotting and immunohistochemistry. An enzyme-linked immunosorbent assay was used to analyze the expressions of interleukin-2 (IL-2) and tumor necrosis factor-α (TNF-α).
RESULTS: YKF combined with DDP significantly inhibited the growth and metastasis of tumors relative to the control group, and YKF groups (P < 0.05). There was no significant difference between high-dose YKF group and low-dose YKF group (P > 0.05). We also found that the expression levels of TGF-β1 and Smad3 were both significantly decreased by YKF relative to the control group (P < 0.05). Furthermore, after treatment with YKF combined with DDP, the expression levels of TGF-β1 and Smad3 were decreased but the expression level of Smad7 was increased relative to the DDP group (P < 0.05). Compared to the DDP group, the combination of YKF and DDP enhanced the effect of tumor inhibition (P < 0.05), showing obvious synergy between YKF and DDP. Treatment with DDP or YKF decreased serum levels of IL-2 and TNF-α relative to the control group (P < 0.05). Furthermore, the expression levels of IL-2 and TNF-α were significantly decreased when treated with YKF in combination with DDP. Co-treatment with YKF and DDP significantly inhibited tumor growth, decreased the expressions of TGF-β1, Smad3, IL-2 and TNF-α and increased the expression of Smad7; these differences were significant relative to both YKF groups and the control group (P < 0.05).
CONCLUSION: YKF can inhibit tumor growth synergistically with DDP, mainly through the TGF-β1 signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28494854     DOI: 10.1016/S2095-4964(17)60330-3

Source DB:  PubMed          Journal:  J Integr Med


  13 in total

1.  Identification of Key Potential Targets and Pathway for Arsenic Trioxide by Systemic Bioinformatics Analysis in Pancreatic Cancer.

Authors:  Yanan Pang; Zhiyong Liu; Shanrong Liu
Journal:  Pathol Oncol Res       Date:  2018-11-30       Impact factor: 3.201

2.  Pathological analysis of the superior mesenteric artery boundary in preoperative computed tomography of resectable pancreatic head adenocarcinoma.

Authors:  Meng Lu; Chun-Hui Yuan; Ling-Fu Zhang; Lian-Yuan Tao; Ying Peng; Li-Mei Guo; Gang Li; Dian-Rong Xiu
Journal:  Oncol Lett       Date:  2019-04-18       Impact factor: 2.967

3.  Omega 3 polyunsaturated fatty acids inhibit cell proliferation by regulating cell cycle in fad3b transgenic mouse embryonic stem cells.

Authors:  Zhuying Wei; Dongfang Li; Lin Zhu; Lei Yang; Chen Chen; Chunling Bai; Guangpeng Li
Journal:  Lipids Health Dis       Date:  2018-09-08       Impact factor: 3.876

4.  miR-125a restrains cell migration and invasion by targeting STAT3 in gastric cancer cells.

Authors:  Liu Yang; Shuguang Zhang; Kai Guo; Hu Huang; Shuai Qi; Jie Yao; Zhihong Zhang
Journal:  Onco Targets Ther       Date:  2018-12-24       Impact factor: 4.147

5.  Identification and analysis of survival-associated ceRNA triplets in prostate adenocarcinoma.

Authors:  Fan Li; Hai Li; Yi Hou
Journal:  Oncol Lett       Date:  2019-08-16       Impact factor: 2.967

6.  lincROR influences the stemness and crizotinib resistance in EML-ALK+ non-small-cell lung cancer cells.

Authors:  Yonghua Yang; Jingyu Huang; Nianlin Xie; Hu Huang; Shaogan Xu; Jun Cai; Shuai Qi
Journal:  Onco Targets Ther       Date:  2018-06-22       Impact factor: 4.147

7.  Fuzheng Kang-Ai decoction enhances the effect of Gefitinib-induced cell apoptosis in lung cancer through mitochondrial pathway.

Authors:  Sumei Wang; Zhiwei Peng; Wenjuan Li; Shunqin Long; Shujing Xiao; Wanyin Wu
Journal:  Cancer Cell Int       Date:  2020-05-24       Impact factor: 5.722

8.  Decoction of Chinese Herbal Medicine Fuzheng Kang-Ai Induces Lung Cancer Cell Apoptosis via STAT3/Bcl-2/Caspase-3 Pathway.

Authors:  Sumei Wang; Shunqin Long; Shujing Xiao; Wanyin Wu; Swei Sunny Hann
Journal:  Evid Based Complement Alternat Med       Date:  2018-06-25       Impact factor: 2.629

9.  SIK1-LNC represses the proliferative, migrative, and invasive abilities of lung cancer cells.

Authors:  Liu Yang; Nianlin Xie; Jingyu Huang; Hu Huang; Shaogan Xu; Zhigang Wang; Jun Cai
Journal:  Onco Targets Ther       Date:  2018-07-19       Impact factor: 4.147

10.  Traditional Chinese Medicine Integrated with Chemotherapy for Stage II-IIIA Patients with Non-Small-Cell Lung Cancer after Radical Surgery: A Retrospective Clinical Analysis with Small Sample Size.

Authors:  Xueyu Zhao; Xiaojun Dai; Shanshan Wang; Ting Yang; Yan Yan; Guang Zhu; Jun Feng; Bo Pan; Masataka Sunagawa; Xiaochun Zhang; Yayun Qian; Yanqing Liu
Journal:  Evid Based Complement Alternat Med       Date:  2018-07-25       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.